End Stage Renal Disease (ESRD) Drug Market Report 2026

End Stage Renal Disease (ESRD) Drug Market Overview

• End Stage Renal Disease (ESRD) Drug market size has reached to $148.55 billion in 2025 • Expected to grow to $304.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.5% • Growth Driver: The Interconnection Of Obesity And Diabetes In Fueling End-Stage Renal Disease (ESRD) Drug Market Growth • Market Trend: Increasing Focus On Product Approvals To Provide Reliable Services To Their Customers • North America was the largest region in 2025.

What Is Covered Under End Stage Renal Disease (ESRD) Drug Market?

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person's kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD). The main end stage renal disease (ESRD) drugs are calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics can be used to reduce PTH in kidney disease stage 5D, depending on serum calcium and phosphorus levels. The various indications include end stage renal disease (ESRD) induced hyperparathyroidism, end stage renal disease (ESRD) induced hyperphosphatemia, and end stage renal disease (ESRD) induced hyperkaliemia. It is distributed by hospital pharmacy, online pharmacy, and retail pharmacy to be used by hospitals, homecare, specialty clinics, and other end users.

What Is The End Stage Renal Disease (ESRD) Drug Market Growth Forecast?

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $304.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to development of precision medicine, expansion of homecare dialysis, integration of ai in patient monitoring, rising investments in esrd r&d, growing adoption of combination therapies. Major trends in the forecast period include personalized esrd drug therapy, home-based dialysis solutions, telemedicine integration in ckd management, advanced drug formulations for secondary complications, increasing adoption of combination therapies.

Global End Stage Renal Disease (ESRD) Drug Market Segmentation

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Calcimimetics: Cinacalcet, Etelcalcetide 2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol 3) By Sterols: Ergocalciferol, Cholecalciferol 4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate 5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate 6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Is The Driver Of The End Stage Renal Disease (ESRD) Drug Market?

Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improved blood sugar control. For instance, in 2023, the World Obesity Federation, a non profit membership organization, projects that by 2035 the economic cost of overweight and obesity will reach US$ 4.32 trillion annually, equivalent to nearly 3% of globaFor instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

Key Players In The Global End Stage Renal Disease (ESRD) Drug Market

Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Global End Stage Renal Disease (ESRD) Drug Market Trends and Insights

Major companies operating in the end-stage renal disease (ESRD) drug market are focusing on product approvals such as Jardiance to drive revenues in their market. Empagliflozin is a drug intended to help persons with type 2 diabetes and to lower the chance of cardiovascular issues in persons with type 2 diabetes who have heart failure or cardiovascular disease. For instance, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc. a US-based pharmaceutical company received FDA approval for Jardiance. Jardiance has been approved for a number of indications, such as lowering the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as well as lowering the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated in patients with type 1 diabetes and those with an eGFR less than 20 ml/min/1.73 m.

What Are Latest Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market?

In May 2024, Vertex Pharmaceuticals, a U.S.-based biotechnology company developing treatments for genetic diseases and immunology, acquired Alpine Immune Sciences for an undisclosed amount. With this acquisition, Vertex aimed to expand its renal disease portfolio by securing povetacicept, Alpine’s lead asset targeting IgA nephropathy (IgAN), a chronic autoimmune kidney disease that can progress to end stage renal disease, and to integrate Alpine’s protein-engineering and immunotherapy capabilities. Alpine Immune Sciences is a U.S.-based clinical-stage biotech focused on engineered immunotherapies, with its dual BAFF/APRIL antagonist povetacicept poised to enter Phase 3 development for IgAN.

Regional Insights

North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the End Stage Renal Disease (ESRD) Drug Market?

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the End Stage Renal Disease (ESRD) Drug Market Report 2026?

The end stage renal disease (esrd) drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (esrd) drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.